‘Making Ground’: An Ethnography of ‘Living With’ Harmful Methamphetamine Use and the Plurality of Recovery

AuthorSamuel Brookfield,Lisa Fitzgerald,Lisa Maher,Linda Selvey
DOI10.1177/00220426211073911
Date01 July 2022
Published date01 July 2022
Subject MatterArticles
Article
Journal of Drug Issues
2022, Vol. 52(3) 366388
© The Author(s) 2022
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/00220426211073911
journals.sagepub.com/home/jod
Making Ground:An
Ethnography of Living With
Harmful Methamphetamine
Use and the Plurality of
Recovery
Samuel Brookf‌ield
1
, Linda Selvey
1
, Lisa Maher
2
, and
Lisa Fitzgerald
1
Abstract
The trajectories of people attempting to reduce harmful methamphetamine use are frequently
understood within a binary framework of transitioning between states of health and disease. This
framework can often be reinforced by service interactions informed by these dominant narratives
of recovery and addiction. In this paper, we draw on a critical interactionist analysis of eth-
nographic f‌ieldwork conducted with people who use methamphetamine, to examine how their
experiences could undermine this binary, observing the ways participants experienced gro wth,
change, and progress, without necessarily maintaining abstinence. These f‌indings support a more
diverse understanding of drug use trajectories, and we explore the concept of living with drug
use, similar to how people live with other chronic conditions by f‌inding health in illness.
Participant experiences are also interpreted within the context of counter public health, argu ing
for the recognition and integration of values and goals which are divergent from the implicit aims
of public health practice.
Keywords
methamphetamine, addiction, recovery, chronic disease, critical
Introduction
“…subjectivities are forged and life patterns are shaped not so much in the clinic or rehabilitation
center as an endpoint, or exclusively in the domain of use,but in the movement between them.
1
School of Public Health, The University of Queensland, Brisbane, Australia
2
Kirby Institute for Infection and Immunity, University of New South Wales, Sydney, Australia
Corresponding Author:
Samuel Brookf‌ield, School of Public Health, The University of Queensland, 266 Herston Road, Brisbane, QLD 4006,
Australia.
Email: samueljbrookf‌ield@gmail.com
Addiction Trajectories: Tracing New Paths in the Anthropology of Addiction, Raikhel and
Garriott (2013)
Methamphetamine use and related harms have increased internationally over the past dec ade
(Degenhardt et al., 2014;Farrell et al., 2019), with many people who use methamphetamine
(PWUM) experiencing impaired functionality and increased rates of depression, suicidali ty and
psychosis (McKetin et al., 2019). Despite the complexity and urgency of understanding how to
reduce harmful methamphetamine use, there has been limited analysis of the social context in
which methamphetamine recovery occurs and how people navigate this process (Alexander,
Obongo, Chavan, Dillon, & Kedia, 2017;Brookf‌ield, Fitzgerald, Selvey, & Maher, 2019;
Cumming, Troeung, Young,Kelty, & Preen, 2016). Transitioning to abstinence from harmful drug
use is often a cyclical, iterative process (McLellan, Lewis, OBrien, & Kleber, 2000;Sellman,
2010) that entails signif‌icant changes in identity and behaviour (Brookf‌ield et al., 2019). In this
paper, we explore the experience of this cyclical process, and the broader concepts of drug use and
recoverywhich shape it, arguing for greater recognition of how some people can be supported to
live withharmful drug use, in the same way people are supported in living with analogous
chronic health conditions.
Methamphetamine Related Harm in Australia
The signif‌icance of this research is derived in part from the urgency of methamphetamine related
harm as a public health issue. In 2016, up to 4.96 million people were dependent on amphetamines
(Degenhardt et al., 2018), with Australia recording nearly the highest prevalence in the world
(Farrell et al., 2019). The Australian Needle and Syringe Program recently released a 25 year
report based on data from 57,000 respondents indicating that prevalence of methamphetamine as
the last drug injected doubled between 2010 and 2019, and was reported by almost half of all
respondents in 2019, a greater prevalence than heroin (Heard, Iversen, Geddes, & Maher, 2020).
Between 2011 and 2016 the number of publicly funded treatment episodes in which metham-
phetamine was the primary drug of concern also doubled in Australia (Australian Institute of
Health and Welfare, 2017b). Use of crystalline methamphetamine versus powder also increased
during this time (Australian Institute of Health and Welfare, 2017a), a form of the drug associated
with an increased risk of harms such as psychosis (Degenhardt et al., 2017).
This study was conducted in the state of Queensland, where methamphetamine related harm
has been particularly acute, with dramatic increases in methamphetamine related hospital pre-
sentations, ambulance calls, and treatment service visits in the last 15 years (Queensland Health,
2017). Prevalence of methamphetamine use has been declining within younger age groups
(Australian Institute of Health and Welfare, 2017b) and increasing among older populations,
particularly injection drug use (Degenhardt et al., 2016;Heard et al., 2020). In 2016, the average
age of PWUM in Australia was 34 years (Australian Institute of Health and Welfare, 2017b).
There is a need therefore to better understand this older population of PWUM, and the role played
by methamphetamine outside of the younger recreational context in which prevalence has his-
torically been higher.
Addiction and Disease
Understanding how people experience methamphetamine recovery requires examining the
concepts upon which it is constructed and presented to people who use drugs (PWUD). The
biomedical perspective on drug use has dominated research agendas, interventions, and public
health messaging for decades (Satel & Lilienfeld, 2013). These regimes have persistently
Brookf‌ield et al. 367

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT